Next Article in Journal
Health Management Program: Factors Influencing Completion of Therapy with High-Dose Interferon Alfa-2b for High-Risk Melanoma
Previous Article in Journal
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 1
10.3747/co.2008.199
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group

by
J. R. Mackey
*,
M. Clemons
,
M.A. Côté
,
D. Delgado
,
S. Dent
,
A. Paterson
,
L. Provencher
,
M.B. Sawyer
and
S. Verma
11560 University Avenue, Edmonton, AB T6G 1Z2, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(1), 24-35; https://doi.org/10.3747/co.2008.199
Submission received: 5 September 2007 / Revised: 9 October 2007 / Accepted: 8 November 2007 / Published: 1 January 2008

Abstract

Trastuzumab has been shown to be an effective therapy for women with breast cancer that overexpresses the human epidermal growth factor receptor 2 (her2) protein. In the pivotal metastatic breast cancer trials, cardiac dysfunction was observed in women treated with trastuzumab and chemotherapy. The incidence and severity of cardiac dysfunction was greatest among patients who received trastuzumab in combination with anthracycline-based therapy. Those findings influenced the design of subsequent trastuzumab trials to include prospective evaluations of cardiac effects and protocols for cardiac monitoring and management. The risk of cardiotoxicity has also driven efforts to develop non-anthracycline-based regimens for women with her2-positive breast cancers. With the increasing use of trastuzumab, particularly in the curative adjuvant setting, the need for a rational approach to the treatment and cardiac management of the relevant patient population is clear. The mandate of the Canadian Trastuzumab Working Group was to formulate recommendations, based on available data, for the assessment and management of cardiac complications during adjuvant trastuzumab therapy. The panel formulated recommendations in four areas: (1) Risk factors for cardiotoxicity; (2) Effects of various regimens (3) Monitoring (4) Management The recommendations published here are expected to evolve as more data become available and experience with trastuzumab in the adjuvant setting grows.
Keywords: early-stage breast cancer; trastuzumab; cardiotoxicity; anthracycline; adjuvant chemotherapy early-stage breast cancer; trastuzumab; cardiotoxicity; anthracycline; adjuvant chemotherapy

Share and Cite

MDPI and ACS Style

Mackey, J.R.; Clemons, M.; Côté, M.A.; Delgado, D.; Dent, S.; Paterson, A.; Provencher, L.; Sawyer, M.B.; Verma, S. Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol. 2008, 15, 24-35. https://doi.org/10.3747/co.2008.199

AMA Style

Mackey JR, Clemons M, Côté MA, Delgado D, Dent S, Paterson A, Provencher L, Sawyer MB, Verma S. Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group. Current Oncology. 2008; 15(1):24-35. https://doi.org/10.3747/co.2008.199

Chicago/Turabian Style

Mackey, J. R., M. Clemons, M.A. Côté, D. Delgado, S. Dent, A. Paterson, L. Provencher, M.B. Sawyer, and S. Verma. 2008. "Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group" Current Oncology 15, no. 1: 24-35. https://doi.org/10.3747/co.2008.199

APA Style

Mackey, J. R., Clemons, M., Côté, M. A., Delgado, D., Dent, S., Paterson, A., Provencher, L., Sawyer, M. B., & Verma, S. (2008). Cardiac Management during Adjuvant Trastuzumab Therapy: Recommendations of the Canadian Trastuzumab Working Group. Current Oncology, 15(1), 24-35. https://doi.org/10.3747/co.2008.199

Article Metrics

Back to TopTop